MT-3724 clinical trials
Also written MT-3724.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses MT-3724 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MT-3724
- 3
Studies by the year they started
4 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2015 | 2 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Molecular Templates, Inc. (4)
Studies
Open first, then newest update. How each study uses MT-3724 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCLTerminatedPhase 1/2Molecular Templates, Inc.NCT02361346Written as MT-3724 Phase 1
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)TerminatedPhase 2Molecular Templates, Inc.NCT03645395Written as MT-3724
- PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's LymphomaTerminatedPhase 2Molecular Templates, Inc.NCT03488251Written as MT-3724
- Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawnPhase 1Molecular Templates, Inc.NCT02556346Written as MT-3724
Codes
What other systems call MT-3724 · ClinicalTrials.gg INT017747
- UNII (FDA) R23ZRN6GWRMT-3724One source FDA
- NCI Thesaurus C120546Anti-CD20-engineered Toxin Body MT-3724One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | R23ZRN6GWR | MT-3724 | One source FDA |
| NCI Thesaurus | C120546 | Anti-CD20-engineered Toxin Body MT-3724 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.